조현병 환자에서 아미설프라이드에 의한 체중증가와 도파민 D2 수용체 유전자다형성의(rs1800497) 연관성

키워드

참고문헌 (45)

1. Allison DB, "Antipsychotic-induced weight gain : a comprehensive research synthesis", Am J Psychiatry, 156, pp.1686~1696 (1999)
2. National Institutes of Health, "Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report", Obes Res, 6(Suppl 2), pp.51S~209S (1998)
3. Wirshing DA, "Schizophrenia and obesity : impact of antipsychotic medications", J Clin Psychiatry, 65(Suppl 18), pp.13~26 (2004)
4. Allison DB, "The impact of weight gain on quality of life among persons with schizophrenia", Psychiatr Serv, 54, pp.565~567 (2003)
5. Weiden PJ, "Obesity as a risk factor for antipsychotic noncompliance", Schizophrenia Research, 66, pp.51~57 (2004)
6. Correll CU, "Antipsychotic drugs and obesity", Trends Mol Med, 17, pp.97~107 (2011)
7. Haas HL, "Histamine in the nervous system", Physiol Rev, 88, pp.1183~1241 (2008)
8. Sargent BJ, "Targeting 5-HT receptors for the treatment of obesity", Curr Opin Pharmacol, 11, pp.52~58 (2011)
9. Strassnig M, "Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons : one-year analysis", Schizophr Res, 93, pp.90~98 (2007)
10. Cheeta S, "Effects of reinforcer sweet-ness and the D2", D3 antagonist raclopride on progressive ratio operant performance, 1995, pp.6, 127~132
11. Wise RA, "Major attenuation of food reward with performance-sparing doses of pimozide in the rat", Can J Psychol, 32, pp.77~85 (1978)
12. Wise RA, "Neuroleptic-induced"anhedonia"in rats : pimozide blocks reward quality of food", Science, 201, pp.262~264 (1978)
13. Salamone JD, "Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse", J Pharmacol Exp Ther, 305, pp.1~8 (2003)
14. Salamone JD, "Dopamine antagonists alter response allocation but do not suppress appetite for food in rats: contrast between the effects of SKF 83566, raclopride, and fenfluramine on a concurrent choice task", Psychopharmacology, 160, pp.371~380 (2002)
15. Grandy DK, "The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP", Am J Hum Genet, 45, pp.778~785 (1989)
16. Thompson J, "D2 dopamine receptor gene(DRD2)Taq1 A polymorphism : reduced dopamine D2 receptor binding in the human striatum associated with the A1allele", Pharmacogenetics, 7, pp.479~484 (1997)
17. Noble EP, "Allelic association of the D2 dopamine receptor gene with cocaine dependence", Drug Alcohol Depend, 33, pp.271~285 (1993)
18. Noble EP, "D2 dopamine receptor gene and cigarette smoking: a reward gene?", Med Hypotheses, 42, pp.257~260 (1994)
19. Comings DE, "The dopamine D2 receptor(DRD2)gene : a genetic risk factor in smoking", Pharmacogenetics, 6, pp.73~79 (1996)
20. Zhang ZJ, "No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response", Acta Pharmacol Sin, 24, pp.235~240 (2003)
21. Perrault G, "Psychopharmacological profile of amisulpride : an antipsychotic drug with presynaptic D2", D3 dopamine receptor antagonist activity and limbic selectivity, 1997, pp.280, 73~82
22. Lee SJ, "A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg", day versus 800 mg, Clin Drug Investig, pp.2012, 32[DOI]
23. Lett TA, "Pharmacogenetics of antipsychoticinduced weight gain : review and clinical implications", Mol Psychiatry, 17, pp.242~266 (2012)
24. Muller DJ, "Systematic analysis of dopamine receptor genes(DRD1-DRD5)in antipsychotic-induced weight gain", Pharmacogenomics J, 12, pp.156~164 (2012)
25. Weinsier RL, "The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity", Am J Med, 105, pp.145~150 (1998)
26. Koob GF, "Drugs of abuse: anatomy, pharmacology and function of reward pathways", Trends Pharmacol Sci, 13, pp.177~184 (1992)
27. Noble EP., "The DRD2 gene in psychiatric and neurological disorders and its phenotypes", Pharmacogenomics, 1, pp.309~333 (2000)
28. Berridge KC, "Food reward : brain substrates of wanting and liking", Neurosci Biobehav Rev, 20, pp.1~25 (1996)
29. Berridge KC, "What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?", Brain Res Brain Res Rev, 28, pp.309~369 (1998)
30. Pohjalainen T, "The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers", Mol Psychiatry, 3, pp.256~260 (1998)
31. Ritchie T, "Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptorbinding characteristics", Neurochem Res, 28, pp.73~82 (2003)
32. Jonsson EG, "Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers", Mol Psychiatry, 4, pp.290~296 (1999)
33. Epstein LH, "Food hedonics and reinforcement as determinants of laboratory food intake in smokers", Physiol Behav, 81, pp.511~517 (2004)
34. Epstein LH, "Food reinforcement and eating : a multilevel analysis", Psychol Bull, 133, pp.884~906 (2007)
35. Epstein LH, "Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers", Am J Clin Nutr, 80, pp.82~88 (2004)
36. Wang GJ, "Brain dopamine and obesity", Lancet, 357, pp.354~357 (2001)
37. Comings DE, "The dopamine D2 receptor(DRD2)as a major gene in obesity and height", Biochem Med Metab Biol, 50, pp.176~185 (1993)
38. Epstein LH, "Food reinforcement, the dopamine D2receptor genotype, and energy intake in obese and nonobese humans", Behav Neurosci, 121, pp.877~886 (2007)
39. Tataranni PA, "A Ser311Cys mutation in the human dopamine receptor D2 gene is associated with reduced energy expenditure", Diabetes, 50, pp.901~904 (2001)
40. Blin O, "Antipsychotic-associated weight gain and clinical outcome parameters", J Clin Psychiatry, 62(Suppl 7), pp.11~21 (2001)
41. Taylor DM, "Atypical antipsychotics and weight gain--a systematic review", Acta Psychiatr Scand, 101, pp.416~432 (2000)
42. Kapur S, "Half a century of antipsychotics and still a central role for dopamine D2 receptors", Prog Neuropsychopharmacol Biol Psychiatry, 27, pp.1081~1090 (2003)
43. Lencz T, "DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia", Pharmacogenet Genomics, 20, pp.569~572 (2010)
44. 김희철, "한국인 정신분열병 환자에서 항정신병 약물에 의한 체중 증가와 도파민 D2, D3 및 D4 수용체 유전자 다형성", 대한정신약물학회지, 18(5), pp.299~307 (2007), 대한정신약물학회
45. Jenkinson CP, "Association of dopamine D2 receptor polymorphisms Ser311Cys and TaqIA with obesity or type 2 diabetes mellitus in Pima Indians", Int J Obes Relat Metab Disord, 24, pp.1233~1238 (2000)

관련 논문AI추천